A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo
Authors:
- Iris PinheiroIPIris Pinheiro
- Aurora BarberáAurora Barberá
- Imma RaurellIRImma Raurell
- Federico EstrellaFEFederico Estrella
- Marcel de LeeuwMLMarcel de Leeuw
- Selin BolcaSBSelin Bolca
- Davide GottardiDGDavide Gottardi
- Nigel HorscroftNHNigel Horscroft
- Sam PossemiersSPSam Possemiers
- María Teresa SalcedoMSMaría Teresa Salcedo
- Joan GenescàJGJoan Genescà
- María MartellMaría Martell
Open Access
- 20 May 2022
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 10 (5) , 1191
Abstract
The gut microbiome has a recognized role in Non-alcoholic fatty liver disease (NAFLD) and associated comorbidities such as Type-2 diabetes and obesity. Stool transplantation has been shown to improve disease by restoring endothelial function and insulin signaling. However, more patient-friendly treatments are required. The present study aimed to test the effect of a defined bacterial consortium of nine gut commensal strains in two in vivo rodent models of Non-alcoholic steatohepatitis (NASH): a rat model of NASH and portal hypertension (PHT), and the Stelic animal (mouse) model (STAM™). In both studies the consortium was administered orally q.d. after disease induction. In the NASH rats, the consortium was administered for 2 weeks and compared to stool transplant. In the STAM™ study administration was performed for 4 weeks, and the effects compared to vehicle or Telmisartan at the stage of NASH/early fibrosis. A second group of animals was followed for another 3 weeks to assess later-stage fibrosis. In the NASH rats, an improvement in PHT and endothelial function was observed. Gut microbial compositional changes also revealed that the consortium achieved a more defined and richer replacement of the gut microbiome than stool transplantation. Moreover, liver transcriptomics suggested a beneficial modulation of pro-fibrogenic pathways. An improvement in liver fibrosis was then confirmed in the STAM™ study. In this study, the bacterial consortium improved the NAFLD activity score, consistent with a decrease in steatosis and ballooning. Serum cytokeratin-18 levels were also reduced. Therefore, administration of a specific bacterial consortium of defined composition can ameliorate NASH, PHT, and fibrosis, and delay disease progression.Keywords
This publication has 56 references indexed in Scilit:
- Molecular Characterization of the Fecal Microbiota in Patients with Nonalcoholic Steatohepatitis – A Longitudinal StudyPLOS ONE, 2013
- phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census DataPLOS ONE, 2013
- A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinomaMedical Molecular Morphology, 2013
- Differential expression analysis for sequence count dataGenome Biology, 2010
- Microbiota and SCFA in Lean and Overweight Healthy SubjectsObesity, 2010
- Thyroid hormone responsive Spot 14 increases during differentiation of human adipocytes and its expression is down-regulated in obese subjectsInternational Journal of Obesity, 2009
- Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease†Hepatology, 2009
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver diseaseHepatology, 2003
- "Spot 14" Protein: A Metabolic Integrator in Normal and Neoplastic CellsThyroid®, 1998